# A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

> **NCT03693573** · PHASE3 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03693573
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-01-11
- **Primary completion:** 2021-08-14
- **Final completion:** 2024-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** In the context of the ongoing evaluation of our data, we have determined that there is no need to generate additional safety data at this time in the 1L mRCC pa
- **Last updated:** 2018-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03693573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03693573, "A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT03693573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*